HTA Quarterly | Summer 2017
We take a look at patient input into HTA decisions in 4 countries, examining new therapies for Duchenne Muscular Dystrophy, and understanding the Colombian universal healthcare model.
Hearing the Patient Voice Loud and Clear
A Look at 4 Countries and Their Use of Input From Patients and Patient Organizations
While health technology assessments (HTAs) aim to produce policies that balance clinical benefit alongside the increased expense, the entity ultimately most affected by these decisions is the patient. Patient and patient advocacy groups are increasingly laying pressure on regulatory and HTA agencies to have more input into the decision-making process. This article will provide a brief snapshot as to how Australia, Canada, England, and Scotland involve patient or patient groups in product assessment decision making.
Therapeutic Spotlight: Duchenne Muscular Dystrophy: New and Revitalized Drugs Bring Hope to Patients
Duchenne muscular dystrophy (DMD) is a devastating muscle-wasting disease that affects only a small number of mostly adolescent males, but the rare disease is making international headlines as new treatments are stimulating current discussions on evidentiary requirements, pricing, and access of pharmaceuticals. In this article, we review the burden of DMD, treatment, and disease management approaches in development, and we examine recent regulatory and health technology assessment (HTA) appraisals.
Colombia: A Unique Universal Healthcare Model in Latin America
Colombia is the second-most populated country in South America after Brazil. The Colombian health sector has been in transition since bold healthcare reform was introduced in 1993, experiencing an increase of overall life expectance and a decreased infant mortality rate. We examine key market considerations of Colombia's unique healthcare model.